When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment journey can help patients feel more informed when discussing their options with their healthcare team. In this educational video, Craig Portell, MD, of the University of Virginia, breaks down the basics of treatment sequencing for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), exploring key differences between BTK- and BCL-2–targeted therapies.